Will Biosimilars Impact the Cost of Specialty Drugs?

Video

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Related Videos
Young depressed woman talking to lady psychologist during session, mental health - Image credit: motortion | stock.adobe.com
man taking opioid pills sitting at a dark table - Image credit: rohane | stock.adobe.com
schizophrenic man - mental disorder - Image credit: Andreza | stock.adobe.com
Related Content
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

April 25th 2024
Article
Pharmacy Focus: Policy Edition - Discussing the DRUG Act and PBM Reform

Pharmacy Focus: Policy Edition - Discussing the DRUG Act and PBM Reform

April 5th 2024
Podcast
Stem cell transplant procedure -- Image credit: Vadim | stock.adobe.com

Advancement in Stem Cell Transplantation: Improving Outcomes for Patients With Blood Cancer

April 25th 2024
Article
Pharmacy Focus: OTC Contraception and Reproductive Health

Pharmacy Focus: OTC Contraception and Reproductive Health

March 29th 2024
Podcast
Artificial intelligence -- Image credit: Shuo | stock.adobe.com

Optimizing Oncological Care: The Influence of AI on Insurance Approvals

April 24th 2024
Article
FDA approval stamp -- Image credit: Olivier Le Moal | stock.adobe.com

FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors

April 23rd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.